The advanced drug delivery systems market size has grown strongly in recent years. It will grow from $285.59 billion in 2025 to $310.15 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to expansion of pharmaceutical R&D activities, rising prevalence of chronic diseases, advancements in formulation science, growth of injectable drug therapies, increased focus on treatment efficacy.
The advanced drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $433.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of biologics, expansion of nanotechnology-based therapies, growing focus on reducing drug side effects, increasing investments in advanced pharmaceutical delivery platforms. Major trends in the forecast period include increasing adoption of targeted drug delivery technologies, rising use of nanocarrier-based formulations, growing demand for controlled release systems, expansion of biologic and biosimilar delivery solutions, enhanced focus on patient-centric drug administration.
The anticipated rise in chronic conditions is poised to drive the expansion of the advanced drug delivery systems market. Chronic conditions, persisting for a year or longer and necessitating ongoing medical care, are attributed to various risk behaviors such as tobacco use, exposure to secondhand smoke, poor nutrition, physical inactivity, and excessive alcohol use. Advanced drug delivery systems play a crucial role in precisely delivering therapeutic agents to specific sites affected by chronic conditions, enhancing drug effectiveness, and minimizing side effects. For example, as per May 2023 data from The United Nations (UN), chronic diseases account for seven out of 10 deaths in the US, causing over 1.7 million fatalities annually. Consequently, the increasing prevalence of chronic conditions underpins the growth of the advanced drug delivery systems market.
Leading players in the advanced drug delivery system landscape are prioritizing the development of innovative approaches, including subcutaneous biologic delivery technologies, to address the growing need for convenient, fast, and patient-centric administration of complex therapies. Subcutaneous biologic delivery allows high volumes of medication to be administered beneath the skin, providing a less invasive option compared with conventional intravenous infusions. For example, in June 2023, Halozyme Therapeutics, Inc. announced approval by the United States Food and Drug Administration for VYVGART Hytrulo with ENHANZE, a novel subcutaneous formulation indicated for generalized myasthenia gravis. This product combines efgartigimod alfa with Halozyme’s recombinant human hyaluronidase PH20 (rHuPH20), enabling rapid, high-volume subcutaneous administration through a single injection. The approach shortens administration time to seconds, enhances patient convenience, enables treatment beyond hospital settings, and preserves clinical effectiveness comparable to intravenous delivery.
In November 2023, Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies for Alzheimer’s disease, entered into a collaboration with Halozyme Therapeutics, Inc. to develop a subcutaneous formulation of ACU193 utilizing ENHANZE technology. Through this collaboration, the companies seek to enhance patient-focused drug delivery by enabling a more convenient and efficient subcutaneous administration of ACU193 while maintaining therapeutic performance. Halozyme Therapeutics, Inc. provides specialized drug delivery solutions, including ENHANZE technology, which supports subcutaneous delivery of biologics and helps reduce the overall treatment burden for patient.
Major companies operating in the advanced drug delivery systems market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, Abbvie Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, 3M Company, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Merck Group, Becton Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Boston Scientific Corporation, Astellas Pharma Inc., Catalent Inc., Nipro Corporation, AptarGroup Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation.
North America was the largest region in the advanced drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the advanced drug delivery systems market by increasing costs of imported polymers, nanoparticles, specialty excipients, delivery devices, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to globalized raw material sourcing, while Asia-Pacific faces higher costs in exporting advanced formulations. These tariffs are increasing development and production expenses. However, they are also encouraging regional sourcing of materials, localized manufacturing, and innovation in cost-optimized drug delivery technologies.
The advanced drug delivery systems market research report is one of a series of new reports that provides advanced drug delivery systems market statistics, including advanced drug delivery systems industry global market size, regional shares, competitors with a advanced drug delivery systems market share, detailed advanced drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the advanced drug delivery systems industry. This advanced drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Advanced drug delivery systems refer to innovative techniques and formulations designed to enhance the targeted distribution, bioavailability, and efficacy of pharmaceutical medications. These systems aim to maximize drug efficacy while minimizing side effects, providing controlled drug release rates, and targeting specific areas of the body.
The main types of advanced drug delivery systems include oral drug delivery systems, injection-based drug delivery systems, inhalation or pulmonary drug delivery systems, transdermal drug delivery systems, transmucosal drug delivery systems, carrier-based drug delivery systems, and others. The oral drug delivery system involves introducing a chemical through the mouth or into the gastrointestinal tract for systemic activity. Carrier types in these systems include liposomes, nanoparticles, microspheres, monoclonal antibodies, and others. Various technologies, such as prodrugs, implants, intrauterine devices, targeted drug delivery, polymeric drug delivery, and others, are employed. These delivery systems find applications in indications such as cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, inflammatory diseases, infections, and more. They are utilized by hospitals, specialized clinics, and clinical research and development centers.
The advanced drug delivery systems market consists of revenues earned by entities by providing stimuli-responsive drug delivery systems, sustained drug delivery systems, targeted drug delivery systems, and nanoparticle-based drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced drug delivery systems market also consists of sales of fentanyl transdermal patches, albuterol inhalers, and hydrogels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The advanced drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $433.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of biologics, expansion of nanotechnology-based therapies, growing focus on reducing drug side effects, increasing investments in advanced pharmaceutical delivery platforms. Major trends in the forecast period include increasing adoption of targeted drug delivery technologies, rising use of nanocarrier-based formulations, growing demand for controlled release systems, expansion of biologic and biosimilar delivery solutions, enhanced focus on patient-centric drug administration.
The anticipated rise in chronic conditions is poised to drive the expansion of the advanced drug delivery systems market. Chronic conditions, persisting for a year or longer and necessitating ongoing medical care, are attributed to various risk behaviors such as tobacco use, exposure to secondhand smoke, poor nutrition, physical inactivity, and excessive alcohol use. Advanced drug delivery systems play a crucial role in precisely delivering therapeutic agents to specific sites affected by chronic conditions, enhancing drug effectiveness, and minimizing side effects. For example, as per May 2023 data from The United Nations (UN), chronic diseases account for seven out of 10 deaths in the US, causing over 1.7 million fatalities annually. Consequently, the increasing prevalence of chronic conditions underpins the growth of the advanced drug delivery systems market.
Leading players in the advanced drug delivery system landscape are prioritizing the development of innovative approaches, including subcutaneous biologic delivery technologies, to address the growing need for convenient, fast, and patient-centric administration of complex therapies. Subcutaneous biologic delivery allows high volumes of medication to be administered beneath the skin, providing a less invasive option compared with conventional intravenous infusions. For example, in June 2023, Halozyme Therapeutics, Inc. announced approval by the United States Food and Drug Administration for VYVGART Hytrulo with ENHANZE, a novel subcutaneous formulation indicated for generalized myasthenia gravis. This product combines efgartigimod alfa with Halozyme’s recombinant human hyaluronidase PH20 (rHuPH20), enabling rapid, high-volume subcutaneous administration through a single injection. The approach shortens administration time to seconds, enhances patient convenience, enables treatment beyond hospital settings, and preserves clinical effectiveness comparable to intravenous delivery.
In November 2023, Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies for Alzheimer’s disease, entered into a collaboration with Halozyme Therapeutics, Inc. to develop a subcutaneous formulation of ACU193 utilizing ENHANZE technology. Through this collaboration, the companies seek to enhance patient-focused drug delivery by enabling a more convenient and efficient subcutaneous administration of ACU193 while maintaining therapeutic performance. Halozyme Therapeutics, Inc. provides specialized drug delivery solutions, including ENHANZE technology, which supports subcutaneous delivery of biologics and helps reduce the overall treatment burden for patient.
Major companies operating in the advanced drug delivery systems market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, Abbvie Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, 3M Company, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Merck Group, Becton Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Boston Scientific Corporation, Astellas Pharma Inc., Catalent Inc., Nipro Corporation, AptarGroup Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation.
North America was the largest region in the advanced drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the advanced drug delivery systems market by increasing costs of imported polymers, nanoparticles, specialty excipients, delivery devices, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to globalized raw material sourcing, while Asia-Pacific faces higher costs in exporting advanced formulations. These tariffs are increasing development and production expenses. However, they are also encouraging regional sourcing of materials, localized manufacturing, and innovation in cost-optimized drug delivery technologies.
The advanced drug delivery systems market research report is one of a series of new reports that provides advanced drug delivery systems market statistics, including advanced drug delivery systems industry global market size, regional shares, competitors with a advanced drug delivery systems market share, detailed advanced drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the advanced drug delivery systems industry. This advanced drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Advanced drug delivery systems refer to innovative techniques and formulations designed to enhance the targeted distribution, bioavailability, and efficacy of pharmaceutical medications. These systems aim to maximize drug efficacy while minimizing side effects, providing controlled drug release rates, and targeting specific areas of the body.
The main types of advanced drug delivery systems include oral drug delivery systems, injection-based drug delivery systems, inhalation or pulmonary drug delivery systems, transdermal drug delivery systems, transmucosal drug delivery systems, carrier-based drug delivery systems, and others. The oral drug delivery system involves introducing a chemical through the mouth or into the gastrointestinal tract for systemic activity. Carrier types in these systems include liposomes, nanoparticles, microspheres, monoclonal antibodies, and others. Various technologies, such as prodrugs, implants, intrauterine devices, targeted drug delivery, polymeric drug delivery, and others, are employed. These delivery systems find applications in indications such as cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, inflammatory diseases, infections, and more. They are utilized by hospitals, specialized clinics, and clinical research and development centers.
The advanced drug delivery systems market consists of revenues earned by entities by providing stimuli-responsive drug delivery systems, sustained drug delivery systems, targeted drug delivery systems, and nanoparticle-based drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced drug delivery systems market also consists of sales of fentanyl transdermal patches, albuterol inhalers, and hydrogels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Advanced Drug Delivery Systems Market Characteristics
3. Advanced Drug Delivery Systems Market Supply Chain Analysis
4. Global Advanced Drug Delivery Systems Market Trends and Strategies
5. Advanced Drug Delivery Systems Market Analysis of End Use Industries
7. Global Advanced Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Advanced Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market
9. Advanced Drug Delivery Systems Market Segmentation
10. Advanced Drug Delivery Systems Market Regional and Country Analysis
11. Asia-Pacific Advanced Drug Delivery Systems Market
12. China Advanced Drug Delivery Systems Market
13. India Advanced Drug Delivery Systems Market
14. Japan Advanced Drug Delivery Systems Market
15. Australia Advanced Drug Delivery Systems Market
16. Indonesia Advanced Drug Delivery Systems Market
17. South Korea Advanced Drug Delivery Systems Market
18. Taiwan Advanced Drug Delivery Systems Market
19. South East Asia Advanced Drug Delivery Systems Market
20. Western Europe Advanced Drug Delivery Systems Market
21. UK Advanced Drug Delivery Systems Market
22. Germany Advanced Drug Delivery Systems Market
23. France Advanced Drug Delivery Systems Market
24. Italy Advanced Drug Delivery Systems Market
25. Spain Advanced Drug Delivery Systems Market
26. Eastern Europe Advanced Drug Delivery Systems Market
27. Russia Advanced Drug Delivery Systems Market
28. North America Advanced Drug Delivery Systems Market
29. USA Advanced Drug Delivery Systems Market
30. Canada Advanced Drug Delivery Systems Market
31. South America Advanced Drug Delivery Systems Market
32. Brazil Advanced Drug Delivery Systems Market
33. Middle East Advanced Drug Delivery Systems Market
34. Africa Advanced Drug Delivery Systems Market
36. Advanced Drug Delivery Systems Market Competitive Landscape and Company Profiles
37. Advanced Drug Delivery Systems Market Other Major and Innovative Companies
40. Advanced Drug Delivery Systems Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Advanced Drug Delivery Systems Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses advanced drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for advanced drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The advanced drug delivery systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Oral Drug Delivery System; Injection-Based Drug Delivery System; Inhalation Or Pulmonary Drug Delivery System; Transdermal Drug Delivery System; Transmucosal Drug Delivery System; Carrier-Based Drug Delivery System; Other Types2) By Carrier Type: Liposomes; Nanoparticles; Microspheres; Other Carrier Types
3) By Technology: Prodrug; Implants And Intrauterine Devices; Targeted Drug Delivery; Polymeric Drug Delivery; Other Technologies
4) By Application: Cardiovascular Diseases; Oncology; Urology; Diabetes; CNS (Central Nervous System); Ophthalmology; Inflammatory Diseases; Infections; Other Applications
5) By End User: Hospitals; Specialized clinics; Clinical Research And Development Centers
Subsegments:
1) By Oral Drug Delivery System: Solid Dosage Forms; Liquid Dosage Forms; Novel Oral Delivery Systems2) By Injection-Based Drug Delivery System: Autoinjectors; Microneedle-Based Systems
3) By Inhalation Or Pulmonary Drug Delivery System: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers; Soft Mist Inhalers
4) By Transdermal Drug Delivery System: Transdermal Patches; Microneedle Patches; Iontophoresis Systems
5) By Transmucosal Drug Delivery System: Buccal Delivery Systems; Sublingual Delivery Systems; Nasal Delivery Systems
6) By Carrier-Based Drug Delivery System: Liposomes; Nanoparticles; Dendrimers; Niosomes
7) By Other Types: Implantable Drug Delivery Systems; Targeted Delivery Systems; Bioadhesive Drug Delivery Systems
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; Roche Holding AG; Abbvie Inc.; Bayer AG; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc; 3M Company; Medtronic plc; Eli Lilly and Company; Boehringer Ingelheim GmbH; Amgen Inc.; Merck Group; Becton Dickinson and Company; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; Boston Scientific Corporation; Astellas Pharma Inc.; Catalent Inc.; Nipro Corporation; AptarGroup Inc.; West Pharmaceutical Services Inc.; Gerresheimer AG; Insulet Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Advanced Drug Delivery Systems market report include:- Pfizer Inc.
- Johnson and Johnson Services Inc.
- Roche Holding AG
- Abbvie Inc.
- Bayer AG
- Novartis AG
- AstraZeneca plc
- GlaxoSmithKline plc
- 3M Company
- Medtronic plc
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Amgen Inc.
- Merck Group
- Becton Dickinson and Company
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Boston Scientific Corporation
- Astellas Pharma Inc.
- Catalent Inc.
- Nipro Corporation
- AptarGroup Inc.
- West Pharmaceutical Services Inc.
- Gerresheimer AG
- Insulet Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 310.15 Billion |
| Forecasted Market Value ( USD | $ 433.56 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
